FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913215587> ?p ?o ?g. }

• W2913215587 abstract "Introduction: Subcutaneously administered immunoglobulin (SCIG) is increasingly used to treat patients with primary immunodeficiencies (PIDs). Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®. Objectives: To investigate the efficacy, safety and tolerability of octanorm in a prospective, open-label, single-arm phase 3 study involving adult and pediatric patients with PIDs (NCT01888484; clinicaltrials.gov/ct2/show/NCT01888484). Methods: Patients who were previously treated with IVIG received a total of 64 weekly SCIG infusions, including 12 weekly infusions during the wash-in/wash-out period, followed by 52 weekly infusions during the evaluation period. Results: A total of 61 patients aged 2-73 years received 3,497 infusions of octanorm. The mean dose per patient was 0.175 g/kg/infusion. The mean calculated dose conversion factor from the patients' previous IVIG dose for octanorm was 1.37. No serious bacterial infections developed during the study. The rate of other infections per person-year during the primary observation period was 3.43 (upper 95% CI 4.57). All but one non-bacterial infection were mild or moderate in intensity. IgG trough levels were constant during the course of the study. Eleven patients (18.0%) experienced 14 mild or moderate systemic adverse events (AEs) related to octanorm. The rate of related AEs per infusion was 0.004. In 76.7% of infusions, no infusion site reactions were observed and only two (0.3%) reactions were deemed severe. The incidence of site reactions decreased with successive infusions. Conclusion: The new 16.5% SCIG octanorm was shown to be efficacious in preventing infections in PIDs, and was well tolerated." @default.
• W2913215587 created "2019-02-21" @default.
• W2913215587 creator A5002674234 @default.
• W2913215587 creator A5008552149 @default.
• W2913215587 creator A5022699593 @default.
• W2913215587 creator A5033747611 @default.
• W2913215587 creator A5058987519 @default.
• W2913215587 creator A5061134160 @default.
• W2913215587 creator A5068501157 @default.
• W2913215587 creator A5078290997 @default.
• W2913215587 creator A5078725375 @default.
• W2913215587 creator A5087341823 @default.
• W2913215587 creator A5090274588 @default.
• W2913215587 date "2019-02-04" @default.
• W2913215587 modified "2023-10-17" @default.
• W2913215587 title "Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies" @default.
• W2913215587 cites W1512865215 @default.
• W2913215587 cites W1522696780 @default.
• W2913215587 cites W1582023997 @default.
• W2913215587 cites W1590526528 @default.
• W2913215587 cites W1899711695 @default.
• W2913215587 cites W1908021215 @default.
• W2913215587 cites W1970367644 @default.
• W2913215587 cites W1979533125 @default.
• W2913215587 cites W1982773941 @default.
• W2913215587 cites W1989484219 @default.
• W2913215587 cites W1990890427 @default.
• W2913215587 cites W1991577923 @default.
• W2913215587 cites W1996732435 @default.
• W2913215587 cites W2010614425 @default.
• W2913215587 cites W2033723524 @default.
• W2913215587 cites W2037581442 @default.
• W2913215587 cites W2045096978 @default.
• W2913215587 cites W2057695882 @default.
• W2913215587 cites W2058522501 @default.
• W2913215587 cites W2058731890 @default.
• W2913215587 cites W2059451555 @default.
• W2913215587 cites W2068576139 @default.
• W2913215587 cites W2076377855 @default.
• W2913215587 cites W2109584619 @default.
• W2913215587 cites W2134565902 @default.
• W2913215587 cites W2134678353 @default.
• W2913215587 cites W2135875157 @default.
• W2913215587 cites W2139592987 @default.
• W2913215587 cites W2166999982 @default.
• W2913215587 cites W2171173998 @default.
• W2913215587 cites W2235970093 @default.
• W2913215587 cites W2275683149 @default.
• W2913215587 cites W2330505390 @default.
• W2913215587 cites W2511870232 @default.
• W2913215587 cites W2519097826 @default.
• W2913215587 cites W2572233504 @default.
• W2913215587 cites W2734599596 @default.
• W2913215587 cites W2774787224 @default.
• W2913215587 cites W2785910756 @default.
• W2913215587 cites W4239649010 @default.
• W2913215587 doi "https://doi.org/10.3389/fimmu.2019.00040" @default.
• W2913215587 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6369354" @default.
• W2913215587 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30778345" @default.
• W2913215587 hasPublicationYear "2019" @default.
• W2913215587 type Work @default.
• W2913215587 sameAs 2913215587 @default.
• W2913215587 citedByCount "15" @default.
• W2913215587 countsByYear W29132155872019 @default.
• W2913215587 countsByYear W29132155872020 @default.
• W2913215587 countsByYear W29132155872021 @default.
• W2913215587 countsByYear W29132155872022 @default.
• W2913215587 countsByYear W29132155872023 @default.
• W2913215587 crossrefType "journal-article" @default.
• W2913215587 hasAuthorship W2913215587A5002674234 @default.
• W2913215587 hasAuthorship W2913215587A5008552149 @default.
• W2913215587 hasAuthorship W2913215587A5022699593 @default.
• W2913215587 hasAuthorship W2913215587A5033747611 @default.
• W2913215587 hasAuthorship W2913215587A5058987519 @default.
• W2913215587 hasAuthorship W2913215587A5061134160 @default.
• W2913215587 hasAuthorship W2913215587A5068501157 @default.
• W2913215587 hasAuthorship W2913215587A5078290997 @default.
• W2913215587 hasAuthorship W2913215587A5078725375 @default.
• W2913215587 hasAuthorship W2913215587A5087341823 @default.
• W2913215587 hasAuthorship W2913215587A5090274588 @default.
• W2913215587 hasBestOaLocation W29132155871 @default.
• W2913215587 hasConcept C126322002 @default.
• W2913215587 hasConcept C159654299 @default.
• W2913215587 hasConcept C187212893 @default.
• W2913215587 hasConcept C188816634 @default.
• W2913215587 hasConcept C197934379 @default.
• W2913215587 hasConcept C203014093 @default.
• W2913215587 hasConcept C2778375690 @default.
• W2913215587 hasConcept C42219234 @default.
• W2913215587 hasConcept C71924100 @default.
• W2913215587 hasConceptScore W2913215587C126322002 @default.
• W2913215587 hasConceptScore W2913215587C159654299 @default.
• W2913215587 hasConceptScore W2913215587C187212893 @default.
• W2913215587 hasConceptScore W2913215587C188816634 @default.
• W2913215587 hasConceptScore W2913215587C197934379 @default.
• W2913215587 hasConceptScore W2913215587C203014093 @default.
• W2913215587 hasConceptScore W2913215587C2778375690 @default.
• W2913215587 hasConceptScore W2913215587C42219234 @default.
• W2913215587 hasConceptScore W2913215587C71924100 @default.
• W2913215587 hasLocation W29132155871 @default.

• next